The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of bacterial infections in humans and other mammals. A new class of small molecules is disclosed that inhibits the bacterial trans-translation/ribosome rescue mechanism and thus blocks infection of host cells by bacteria. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of bacterial infections.

The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of bacterial infections in humans and other mammals. A new class of small molecules is disclosed that inhibits the bacterial trans-translation/ribosome rescue mechanism and thus blocks infection of host cells by bacteria. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of bacterial infections.

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.

A compound represented by a formula (I) or a salt thereof; and a herbicide containing at least one selected from the group consisting of the compound and a salt thereof as an active ingredient.

##STR00001##

wherein R.sup.a and R.sup.b each independently represent a hydrogen atom, a substituted or unsubstituted C.sub.1-6 alkyl group, or the like; X.sup.1 and X.sup.2 each independently represent a hydrogen atom, a substituted or unsubstituted C.sub.1-6 alkyl group, or the like; X.sup.3 represents a hydrogen atom, a substituted or unsubstituted C.sub.1-6 alkyl group, or a halogeno group; X.sup.4 represents a hydrogen atom or a halogeno group; R.sup.2 represents a substituted or unsubstituted C.sub.1-6 alkyl group, or the like; Q represents a group represented by a formula (Q1), or the like; and in the formula (Q1), an asterisk (*) indicates a bonding position with an R.sup.a-substituted nitrogen atom, and each R.sup.1 independently represents a hydrogen atom or a substituted or unsubstituted C.sub.1-6 alkyl group.

The present invention is directed to oxadiazole linkers and use thereof, more specifically to the compounds represented by formula I, II, and III, and their use in the preparation of antibody-drug conjugates (ADCs). The ADCs obtained from said oxadiazole linkers have high homogeneity and stability, and could be used effectively for the treatment of various diseases including tumors. The definition of the groups in formula I, II, and III is the same as that in the description. ##STR00001##

The present invention is directed to oxadiazole linkers and use thereof, more specifically to the compounds represented by formula I, II, and III, and their use in the preparation of antibody-drug conjugates (ADCs). The ADCs obtained from said oxadiazole linkers have high homogeneity and stability, and could be used effectively for the treatment of various diseases including tumors. The definition of the groups in formula I, II, and III is the same as that in the description. ##STR00001##

The present invention relates to compounds of Formula (I), ##STR00001##
along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).

These compounds are glutamine transporter inhibitors, e.g., alanine, serine, cysteine-preferring transporter 2 (ASCT2) inhibitors. Glutamine transporter inhibitors are useful to treat a variety of diseases, disorders, or conditions including cancer.

These compounds are glutamine transporter inhibitors, e.g., alanine, serine, cysteine-preferring transporter 2 (ASCT2) inhibitors. Glutamine transporter inhibitors are useful to treat a variety of diseases, disorders, or conditions including cancer.